undamentalytics Newsletter
Sign in

Indaptus Therapeutics, Inc. (INDP) stock

Add to watchlist

Add holding +

NASDAQ: INDP Nasdaq Biotechnology Next results ~November 13, 2026

Indaptus Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

The Fundamentalytics view

Next results ~November 13, 2026 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 111% in the quarter to 2025-12-31.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Indaptus Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 13 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 205% and a beta of 1.9 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results

Earnings per share
-$9.19 against an average estimate of -$4.36: missed by 110.8%
Share reaction
+4.9% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500

Indaptus Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+13.3%
  • 1 week+4.8%
  • 1 month+47.1%
  • This year+20.3%
  • 1 year+8.7%
  • 5 years-98.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 13, 2026
Next results (est.)
November 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Agreement
  3. Agreement
  4. Leadership
  5. Agreement
  6. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Indaptus Therapeutics, Inc. valuation models and calculator

No model value for Indaptus Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Indaptus Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.95 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Indaptus Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Indaptus Therapeutics, Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Dec 2025 −$4.36 −$9.19 −110.8%
Sept 2025 −$4.17 −$2.98 +28.5%
Jun 2025 −$9.24 −$9.09 +1.6%
Mar 2025 −$5.04 −$8.96 −77.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
2.1%
of tradable shares
Days to cover
1.21
at average volume
Short interest, 1 month
−7%
to October 15, 2026
Held by institutions
0%
of shares
Held by insiders
70.7%
of shares
Employees
5
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
INDP−59%−75%+21%−52%−88%+20%
Industry peers (median)−35%−56%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
INDP17%17%50%25%33%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
INDP−83%−78%−56%−70%−94%−80%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from September 26, 2017 to August 18, 2026. Getting back needed a 2285370% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.94 – $4.75
From 52-week high
−26.3%
vs 50-day average
+35.1%
vs 200-day average
+52.7%
Volatility (1 year)
205%
Beta vs S&P 500
1.86

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±5.1%
After a week
4 up, 8 down
typical move ±15.1%
After a month
5 up, 7 down
typical move ±50.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 +4.9% +0.5% +35.3% +207.8%
May 15, 2026 −13.1% −1.3% −30.3% +112.6%
November 12, 2025 +8.8% −1.6% −23.9% −10.3%
August 13, 2025 −5.2% +0.4% −10.0% −68.7%
May 14, 2025 −4.5% +0.6% −13.6% −26.1%
March 13, 2025 −4.2% +0.7% −10.1% −42.9%
November 12, 2024 −2.9% −0.3% −14.9% −16.5%
August 12, 2024 −1.8% +1.7% −3.5% −9.4%
May 8, 2024 +1.7% +0.6% +10.7% +29.3%
March 13, 2024 −7.7% −0.4% +12.1% +33.8%
November 6, 2023 −3.6% +0.5% −11.2% −12.9%
August 14, 2023 −2.6% −0.6% +5.7% +36.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

13F filings for June 30, 2026
Reported value
$1.2M
Institutions reporting
9
Shares held vs prior quarter
▲ 445.1%
Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
HRT Financial LP $618,000 206K 53.5% New
Geode Capital Management, LLC $169,410 56K 14.7% ▲ 109.1%
Jane Street Group, LLC $161,433 54K 14.0% New
Vanguard Capital Management LLC $100,956 34K 8.7% New
Vanguard Fiduciary Trust Co $41,901 14K 3.6% New
Millennium Management LLC $34,758 12K 3.0% New
Morgan Stanley $26,808 9K 2.3% ▲ 231.3%
UBS Group AG $1,434 0K 0.1% New
Sbi Securities Co., Ltd. $51 0K 0.0% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Indaptus Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 13, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 15, 2026
  • November 12, 2025
  • August 13, 2025
  • May 14, 2025
  • March 13, 2025

Recent SEC filings

Data status

When each part of this page on Indaptus Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Indaptus Therapeutics, Inc. in brief

What does Indaptus Therapeutics, Inc. do?
Indaptus Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Indaptus Therapeutics, Inc.'s stock ticker?
Indaptus Therapeutics, Inc. trades under the ticker INDP on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Indaptus Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are HRT Financial LP, Geode Capital Management, LLC and Jane Street Group, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
When is Indaptus Therapeutics, Inc.'s next earnings date?
Around November 13, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Indaptus Therapeutics, Inc. announces its own schedule.